Get the Stockscreener App
2.99
1.97%
-0.06
Kiora Pharmaceuticals Inc stock is traded at $2.99, with a volume of 31,483.
It is down -1.97% in the last 24 hours and down -1.32% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.05
Open:
$3.0951
24h Volume:
31,483
Relative Volume:
0.07
Market Cap:
$9.10M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.2084
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-5.97%
1M Performance:
-1.32%
6M Performance:
-21.93%
1Y Performance:
-36.25%
1-Day Range:
$2.99
$3.10
1-Week Range:
$2.96
$3.2328
52-Week Range:
$2.51
$4.80
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
781-788-8869
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Compare KPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.99 | 9.28M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
What drives Kiora Pharmaceuticals Inc. stock priceDynamic investment opportunities - Autocar Professional
What analysts say about Kiora Pharmaceuticals Inc. stockPhenomenal trading returns - PrintWeekIndia
Kiora Pharmaceuticals Secures US Patent for KIO-104 - Ophthalmology Times
Kiora Pharmaceuticals Inc. Stock Analysis and ForecastExtraordinary market timing - Autocar Professional
Is Kiora Pharmaceuticals Inc. a good long term investmentPowerful profit generation - jammulinksnews.com
KPRX Receives Positive Outlook Following New U.S. Patent | KPRX Stock News - GuruFocus
Kiora Pharmaceuticals stock rises after receiving patent for KIO-104 - Investing.com India
Kiora Pharmaceuticals stock rises after receiving patent for KIO-104 By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals receives patent for ocular disease treatment By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals receives patent for ocular disease treatment - Investing.com Australia
Kiora Secures Crucial Patent for Eye Disease Drug KIO-104 as Phase 2 Trial Advances - Stock Titan
Why Kiora Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Retinitis Pigmentosa Treatment Market Driven by Gene Therapy - openPR.com
How Kiora Pharmaceuticals Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
What makes Kiora Pharmaceuticals Inc. stock price move sharplyPredictable Return Stock Picks - Newser
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.8% Higher – Here’s Why - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.3% – Here’s Why - Defense World
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia - Ophthalmology Times
kiora pharmaceuticals reports results of annual shareholder meeting By Investing.com - Investing.com South Africa
kiora pharmaceuticals reports results of annual shareholder meeting - Investing.com
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors - TipRanks
Oil Prices Climb While US Equity Futures Stutter - Finimize
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard SurgeMore Stocks Inside! - openPR.com
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside! - FinancialContent
Markets | American Financial Group, Inc. - FinancialContent
Kiora Pharmaceuticals inks potential $110 million deal with Senju By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiora Pharmaceuticals Inc Stock (KPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shapiro Aron | Director |
Sep 10 '24 |
Buy |
3.60 |
3,000 |
10,800 |
3,000 |
| Walters-Hoffert Lisa | Director |
Aug 19 '24 |
Buy |
3.86 |
1,250 |
4,825 |
1,250 |
| TYLE PRAVEEN | Director |
Aug 19 '24 |
Buy |
3.96 |
5,000 |
19,800 |
5,014 |
| Tosca Melissa | CFO |
Aug 14 '24 |
Buy |
3.21 |
2,000 |
6,420 |
13,599 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):